- Home
- PHUN vs ONCY Comparison
PHUN vs ONCY Comparison
Compare PHUN & ONCY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | PHUN | ONCY |
|---|---|---|
| Founded | 2009 | 1998 |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | EDP Services | Pharmaceuticals and Biotechnology |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 55.9M | 106.1M |
| IPO Year | N/A | 1999 |
Fundamental Metrics
Financial Performance| Metric | PHUN | ONCY |
|---|---|---|
| Price | $2.05 | $1.02 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 6 |
| Target Price | ★ $7.25 | $6.00 |
| AVG Volume (30 Days) | 158.6K | ★ 690.3K |
| Earning Date | 11-06-2025 | 11-12-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $2,357,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $73.07 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.83 | $0.33 |
| 52 Week High | $6.29 | $1.51 |
Technical Indicators
Market Signals| Indicator | PHUN | ONCY |
|---|---|---|
| Relative Strength Index (RSI) | 39.75 | 46.86 |
| Support Level | $2.01 | $0.94 |
| Resistance Level | $2.16 | $1.01 |
| Average True Range (ATR) | 0.09 | 0.06 |
| MACD | 0.02 | 0.01 |
| Stochastic Oscillator | 41.38 | 69.83 |
Price Performance
Historical ComparisonAbout PHUN Phunware Inc.
Phunware Inc is a software company. It is a cloud platform for mobile that provides companies with the products, solutions, and data and services necessary to engage, manage and monetize its mobile application audiences. It derives maximum revenue from United States. The company has two reportable segments: Software subscriptions and services; and Advertising. It derives maximum revenue from Software subscriptions and services.
About ONCY Oncolytics Biotech Inc.
Oncolytics Biotech Inc is a clinical-stage biopharmaceutical company. The company is focused on the discovery and development of pharmaceutical products for the treatment of cancers that have not been treated with therapeutics. It is developing pelareorep, an immunotherapeutic agent that improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The other projects in the company's pipeline include Bracelet-1 for the treatment of Breast Cancer, Goblet cohort-1, and Goblet cohort-5 for the treatment of Gastro-Intestinal Cancer among others.